Insulin in combination with cisplatin induces the apoptosis of ovarian cancer cells via p53 and JNK activation

Zhao,Ting; Bai,Jun; Zou,Qingyun; Chen,Feng; Xie,Yan

doi:10.3892/mmr.2017.7752

Insulin in combination with cisplatin induces the apoptosis of ovarian cancer cells via p53 and JNK activation

Authors:
- Ting Zhao
- Jun Bai
- Qingyun Zou
- Feng Chen
- Yan Xie
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Jiading Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai 201800, P.R. China, Department of Vascular and Endovascular Surgery, Changzheng Hospital Affiliated to The Second Military Medical University, Shanghai 200003, P.R. China, Department of Obstetrics and Gynecology, Xuzhou Central Hospital, Xuzhou, Jiangsu 221004, P.R. China
Published online on: October 10, 2017 https://doi.org/10.3892/mmr.2017.7752
Pages: 9095-9101

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Drug resistance is an obstacle to effective treatment of ovarian cancer. There have been substantial evidences supporting the association between diabetes and the sensitivity to chemotherapy. Insulin (INS) is believed to be the strongest, most lasting hypoglycemic drug. Therefore, the present study aimed to elucidate whether insulin could facilitate the anti‑proliferative activities of cisplatin (cis‑diamminedichloroplatinum, DDP) in the A2780 ovarian cancer cell line. The inhibitory effects of DPP with/without INS on the growth of A2780 cells was measured by MTT assay. The cell cycle stages and levels of apoptosis were determined by flow cytometry. The amounts of signaling elements involved in the regulation of were examined using western blotting and reverse transcription‑quantitative polymerase chain reaction analysis. The results indicated that INS pre‑treatment enhanced the inhibitory effect of DDP on the proliferation of A2780 cells, and facilitated the apoptosis induced by DDP. INS‑DDP treatment led to a marked decrease in the percentage of G0/G1 phase cells, but a corresponding increase in the proportion of S phase cells. Furthermore, A2780 cells pretreated with INS followed by DDP upregulated the protein expression level of phosphorylated c‑Jun N‑terminal kinase (JNK), which resulted in a substantial increase in the expression levels of p53 mRNA and protein, compared with DDP administration alone. In conclusion, the combination of INS and DDP facilitated the apoptosis of A2780 cells, which may be associated with the activation of the JNK signaling pathway and consequently the involvement of p53 at both mRNA and protein expression levels. These results may be useful in furthering our understanding of the mechanisms involved in the chemotherapeutic treatment of ovarian cancer.

View Figures

View References

1	Seeber LM and Van Diest PJ: Epigenetics in ovarian cancer. Methods Mol Biol. 863:253–269. 2012. View Article : Google Scholar : PubMed/NCBI
2	Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB III and Fuchs CS: Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 21:433–440. 2003. View Article : Google Scholar : PubMed/NCBI
3	Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L, Vannelli GB, Brand R, Goldfine ID and Vigneri R: Elevated insulin receptor content in human breast cancer. J Clin Invest. 86:1503–1510. 1990. View Article : Google Scholar : PubMed/NCBI
4	Belfiore A: The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des. 13:671–686. 2007. View Article : Google Scholar : PubMed/NCBI
5	Bartucci M, Morelli C, Mauro L, Andò S and Surmacz E: Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res. 61:6747–6754. 2001.PubMed/NCBI
6	Miglietta A, Panno ML, Bozzo F, Gabriel L and Bocca C: Insulin can modulate MCF-7 cell response to paclitaxel. Cancer Lett. 209:139–145. 2004. View Article : Google Scholar : PubMed/NCBI
7	Zou K, Ju JH and Xie H: Pretreatment with insulin enhances anticancer functions of 5-fluorouracil in human esophageal and colonic cancer cells. Acta Pharmacol Sin. 28:721–730. 2007. View Article : Google Scholar : PubMed/NCBI
8	Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF and Macaulay VM: Expression of the type 1 insulin like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 62:2942–2950. 2002.PubMed/NCBI
9	Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L and Pollak M: Insulin receptor expression by human prostate cancers. Prostate. 96:33–40. 2009. View Article : Google Scholar
10	Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, et al: Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 68:10238–10246. 2008. View Article : Google Scholar : PubMed/NCBI
11	DeVita VT: Dose-response is alive and well. J Clin Oncol. 4:1157–1159. 1986. View Article : Google Scholar : PubMed/NCBI
12	Minden A and Karin M: Regulation and function of the JNK subgroup of MAP kinases. Biochim Biophys Acta. 1333:F85–104. 1997.PubMed/NCBI
13	Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
14	Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, Avruch J and Woodgett JR: The stress-activated protein kinase subfamily of c-Jun kinase. Nature. 369:156–160. 1994. View Article : Google Scholar : PubMed/NCBI
15	Li-Weber M: New therapeutic aspects of flavones: The anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev. 35:57–68. 2009. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Osborne CK, Bolan G, Monaco ME and Lippman ME: Hormone responsive human breast cancer in long-term tissue culture: Effect of insulin. Proc Natl Acad Sci USA. 73:pp. 4536–4540. 1976; View Article : Google Scholar : PubMed/NCBI
18	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
19	Crescenzi E, Chiaviello A, Canti G, Reddi E, Veneziani BM and Palumbo G: Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299). Mol Cancer Ther. 5:776–785. 2006. View Article : Google Scholar : PubMed/NCBI
20	Weston CR and Davis RJ: The JNK signal transduction pathway. Curr Opin Genet Dev. 12:14–21. 2002. View Article : Google Scholar : PubMed/NCBI
21	Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V, Foti D, Chiefari E and Brunetti A: Insulin resistance and cancer risk: An overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012:7891742012. View Article : Google Scholar : PubMed/NCBI
22	Weroha SJ and Haluska P: The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am. 41:335–350. 2012. View Article : Google Scholar : PubMed/NCBI
23	Ichijo H: From receptors to stress-activated MAP kinase. Oncogene. 18:6087–6093. 1999. View Article : Google Scholar : PubMed/NCBI
24	Bogoyevitch MA: The isoform-specific functions of the c-Jun N-terminal Kinases (JNKs): Differences revealed by gene targeting. Bioessays. 28:923–934. 2006. View Article : Google Scholar : PubMed/NCBI